Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14989523 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1340804 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9503018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| Octane SCHEMBL16440085 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345503 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1066766 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2016841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1517931 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL571427 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL136430 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099463-A1 | Sustained Release Pharmaceutical Composition of Upadacitinib | RENATA PHARMACEUTICALS (IRELAND) LIMITED (IE) | 2025-03-27 | — | — | US | disclosed |
| EP-4465971-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION OF UPADACITINIB | Renata Phramaceutical (Ireland) Limited (IE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023138804-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION OF UPADACITINIB | RENATA PHARMACEUTICAL (IRELAND) LIMITED (IE) | 2023-07-27 | — | — | WO | disclosed |
| EP-3045043-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3045043-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2448406-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2013030726-A1 | PROGRAMMED DRUG DELIVERY | WOCKHARDT LIMITED (IN) | 2013-03-07 | — | — | WO | disclosed |
| EP-2448406-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120065221-A1 | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use | THERAQUEST BIOSCIENCES, INC. (PA) | 2012-03-15 | — | — | US | disclosed |
| WO-2010099508-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20080038342-A1 | Stable Pharmaceutical Composition Comprising an Ace Inhibitor | NICHE GENERICS LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| EP-1729812-A1 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACE INHIBITOR | Niche Generics Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005082420-A1 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACE INHIBITOR | NICHE GENERICS LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
| EP-0319126-B1 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | KAO CORP (JP) | 1995-11-08 | — | — | EP | disclosed |
| US-5461170-A | Diglyceride from branched and straight chain fatty acids | KAO CORPORATION (JP) | 1995-10-24 | — | — | US | disclosed |
| EP-0658629-A1 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1995-06-21 | — | — | EP | disclosed |
| EP-0319126-A2 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038342-A1 | Stable Pharmaceutical Composition Comprising an Ace Inhibitor | ACE, ACE2, AGT | FAAH 49/4885CES1 216/4885CES2 700/4885 |
| US-20250099463-A1 | Sustained Release Pharmaceutical Composition of Upadacitinib | PLAUR, JAK1, P2RY13 | FAAH 1469/4885CES1 1410/4885CES2 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.